You are here: Industry Insights > Azacitidine

News List

Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid prnasia
August 02, 2021
Servier, a global pharmaceutical company, today announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO (ivosidenib tablets) in combination with the chemotherapy azacitidine in adults with previously untreated ...
FDA grants BTD for Venclexta in combination with azacitidine to treat patients with myelodysplastic syndromes expresspharma
July 22, 2021
Every year, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the US, and there remains a high unmet need for new treatment options.
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia worldpharmanews
May 26, 2021
Roche announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ...
AbbVie's Venclyxto shows promise as AML treatment pharmatimes
June 17, 2020
AbbVie has presented new data showing the potential of Venclyxto (venetoclax) to reduce the risk of death in previously untreated patients with acute myeloid leukaemia (AML) who were ineligible for intensive chemotherapy.
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML pharmaceutical-business-review
March 27, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination ...
AbbVie Announces Positive Results from VENCLEXTA, Azacitidine Combination for AML americanpharmaceuticalreview
March 26, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in combination with azacitidine versus azacitidine in combination ...
Armas Announces Launch of Azacitidine for Injection to US Market .americanpharmaceuticalreview
November 20, 2018
Armas Pharmaceuticals is announcing the launch of their first injectable to the U.S. market, Azacitidine for Injection 1
Azacitidine and nivolumab combo proves successful in phase II trial pharmatimes
November 14, 2018
A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or refractory
DRL launches generic Azacitidine for Injection in Canada expressbpd
November 06, 2017
Dr Reddy’s Laboratories (DRL) announced that generic Azacitidine for injection 100 mg/vial, a bioequivalent generic version of VIDAZA (azacitidine for injection), is approved by Health Canada.
Breckenridge Announces Final ANDA Approval for Azacitidine for Injection americanpharmaceuticalreview
June 27, 2017
Breckenridge Pharmaceutical announced the FDA has granted final approval of its ANDA Azacitidine for Injection, 100mg per vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.